A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Lower respiratory tract; Gastro-intestinal tract; Urinary tract; Haematological.
30 days post surgery
Terence M Jones, MD
University of Liverpool
United Kingdom: National Health Service